Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene-Guided dosing may tame dangerous fungal infections in blood cancer

NCT ID NCT06510699

Disease control Sponsor: The University of Queensland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a patient's genetic profile to dose the antifungal drug voriconazole can help more patients reach the right drug levels faster. It will enroll 104 children and adults with blood cancer who have a fungal infection. Participants are randomly assigned to either standard dosing or dosing guided by a genetic test and computer software. The goal is to see if personalized dosing improves treatment success and is practical for hospitals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
voriconazole
What this could lead to
If successful, this could make antifungal treatment safer and more effective for people with blood cancer, reducing side effects and improving outcomes.
What could go wrong
This is a small Phase 2 trial, so results may not apply to everyone. Genetic testing may not always lead to better dosing, and the approach may be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 104 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 2 years. * Written informed consent obtained. * Decision to prescribe voriconazole. * Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible Exclusion Criteria: * Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA * Death is likely imminent within 7 days. * Previously randomised to this trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fungal infectious disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Infections infectious disease neoplasm systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood cancer Fungal infection Haematological malignancy Infectious disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Children's Hospital Queensland

    RECRUITING

    South Brisbane, Queensland, 4029, Australia

  • Fred Hutchinson Cancer Centre

    RECRUITING

    Seattle, Washington, 908109-1024, United States

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3053, Australia

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Royal Brisbane & Women's Hospital

    RECRUITING

    Brisbane, Queensland, 4029, Australia

  • Sydney Children's Hospital Network

    RECRUITING

    Sydney, New South Wales, 21452031, Australia

  • Westmead Hospital

    RECRUITING

    Sydney, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.